BioNTech SE (BNTX) is in Healthcare, Biotechnology, based in Germany, listed on NasdaqGS. Market cap 23.70B USD. 52-week range 79.52 to 124.00 USD. Data as of 2026-10-09.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin ...